more DMARDs, such as
methotrexate or TNF antagonists. ORENCIA may be used as monotherapy
or concomitantly with DMARDs other than TNF antagonists. ORENCIA
should not be administered concomitantly with TNF antagonists and
is not recommended for use concomitantly with anakinra.
ORENCIA, which was discovered and developed by Bristol-Myers
Squibb Company, is a selective modulator of a co-stimulatory signal
required for full T-cell activation and works in a fundamentally
different way than cytokine antagonists, including TNF
antagonists.
Bristol-Myers Squibb Company is a global pharmaceutical and
related health care products company whose mission is to extend and
enhance human life.
CONTACT: media, Sarah Koenig, +1-609-252-4145, or
+1-908-397-5379, or, or investors, John Elicker, +1-212-546-3775,
or, both of Bristol-Myers Squibb Company sarah.koenig@bms.com john.elicker@bms.com
Web site: http://www.bms.com/http://www.ORENCIA.com/
Ticker Symbol: (NYSE:BMY)
Terms and conditions of use apply
Copyright © 2007 PR Newswire Association LLC. All rights
reserved.
A United Business Media Company
'"/>Page: 1 2 3 4 5 6 Related medicine technology :1.
Phase 3 Results for Dabigatran Etexilate, an Investigational Oral
Anticoagulant, Presented Today at the XXIst Congress of the
International Society on Thrombosis and Haemostasis2.
An Investigational Study Released at ADA Showed that Initial
Combination Therapy with Januvia (sitagliptin) and Metformin Led to
Improvement in Markers of Beta Cell Function in Patients with Type
2 Diabetes3.
Late Breaking Data Released at ADA Showed that the Investigational
Use of Januvia and Metformin as Initial Combination Therapy
Provided Significant Glucose Lowering Efficacy over 54 Weeks in
Patients with Type 2 Diabetes4.
Mercks Investigational Migraine Treatment MK-0974 Significantly
Improved Migraine Pain on Several Efficacy Measures in a Phase II
Study5.
Data Demonstrated Metastatic Melanoma Response to Investigational
Immunotherapy Ipilimumab6.
Investigational Drug Cediranib (AZD2171) Shows Promise in Patients
With Recurrent Glioblastoma (GBM)7.
Additional New Data from Satraplatin SPARC Phase 3 Investigational
Trial Presented at ASCO Annual Meeting8.
Additional New Data from Satraplatin SPARC Phase 3 Investigational
Trial Presented at ASCO Annual Meeting9.
Investigational Cancer Drug Pertuzumab Shows Promising Results in
Advanced Breast Cancer When Combined with Herceptin10.
Shire Announces Positive Results of Studies With Guanfacine
Extended Release, An Investigational Nonstimulant Medication Filed
for the Treatment of ADHD in Children and Adolescents11.
Investigational Study Evaluates the Effectiveness of Aripiprazole
in Adolescents With Schizophrenia